Revelation Biosciences Inc. is a clinical-stage life sciences company. It focused on the development of immunologic-based therapies for the prevention and treatment of disease. The company's product pipeline includes REVTx-99, REVTx-200 and REVDx-501. Revelation Biosciences Inc., formerly known as Petra Acquisition Inc., is based in NEW YORK.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-15.04M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.29 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -299.46% |
| Return on Assets (Trailing 12 Months) | -115.36% |
| Current Ratio (Most Recent Fiscal Quarter) | 3.60 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.60 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $27.05 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-6.33 |
| Earnings per Share (Most Recent Fiscal Year) | $-138.07 |
| Diluted Earnings per Share (Trailing 12 Months) | $-307.86 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 1.53M |
| Free Float | 1.50M |
| Market Capitalization | $4.28M |
| Average Volume (Last 20 Days) | 0.20M |
| Beta (Past 60 Months) | -0.08 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 2.30% |
| Percentage Held By Institutions (Latest 13F Reports) | 12.80% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |